Abstract: The present invention is directed to aqueous based formulations of water-soluble prodrugs of propofol. The formulations comprise in aqueous medium an effective amount of the water-soluble prodrug of propofol in the absence of an antioxidant. The formulations are particularly useful as intravenous injections. The formulations preferably are buffered to a pH suitable for minimizing degradation of the prodrug during storage. The formulations can be prepared without the use of harmful co-solvents or surfactants and are stable at room temperature over extended periods of time.
Type:
Application
Filed:
September 20, 2007
Publication date:
December 9, 2010
Applicant:
EISAI CORPORATION OF NORTH AMERICA
Inventors:
Kanaiyalal R. Patel, Stephen Dordunoo, David Keller
Abstract: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
Type:
Application
Filed:
August 13, 2009
Publication date:
December 3, 2009
Applicant:
Eisai Corporation of North America
Inventors:
Vincent J. Kalish, Jie Zhang, Weizheng Xu, Jia-He Li, Amy Dongxia Xing, Qun Liu
Abstract: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
Type:
Grant
Filed:
October 20, 2008
Date of Patent:
October 13, 2009
Assignee:
Eisai Corporation of North America
Inventors:
Vincent Kalish, Jie Zhang, Weizheng Xu, Jia-He Li, Amy D. Xing, Qun Liu
Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
Type:
Application
Filed:
January 16, 2009
Publication date:
October 1, 2009
Applicant:
Eisai Corporation of North America
Inventors:
Keith Branham, Mahesh V. Chaubal, James P. English, Donna Hall, Zhong Zhao
Abstract: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-? activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma.
Abstract: A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing water-soluble phosphonooxymethyl derivatives comprises the steps of: R—OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R1 is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R2 is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.
Type:
Grant
Filed:
October 26, 2006
Date of Patent:
May 19, 2009
Assignee:
Eisai Corporation of North America
Inventors:
George Bonneville, Greg Delahanty, Andrew J. Walz